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A B S T R A C T
Background: Clinical outcomes were compared among patients with previous cardiac surgery
undergoing transcatheter aortic valve implantation (TAVI) or surgical aortic valve replacement (AVR).
Methods: Between 2007 and 2014 a total of 142 consecutive patients with previous cardiac surgery were
treated by TAVI either by the transfemoral (n = 68) or transapical access (n = 74), and 236 patients
underwent a surgical redo-AVR. Of these patients, propensity analysis (m:n) matched 62 (group 1, TAVI)
and 51 patients (group 2, redo-AVR). A multivariate logistic regression model was constructed.
Moreover, mortality was compared between both groups by Cox regression.
Results: Both groups differed signiﬁcantly (p < 0.01) in regard to age and preoperative risk scores
(EuroSCORE and STS-Score). Thirty-day mortality was 14.5% (9/62) in group 1 and 5.8% (3/51) in group 2
(p = 0.23). Risk-adjusted multivariable analysis revealed only the logistic EuroSCORE to be strongly
correlated with 30-day mortality (p = 0.01). Multivariate analysis showed no difference in 30-day
mortality between both groups (p = 0.21). Multivariate Cox regression revealed New York Heart
Association functional class (p = 0.001), logistic EuroSCORE (p = 0.01), and STS-Score (p = 0.03) to be
strongly associated with overall mortality. Moreover, evaluating overall mortality, Cox regression
showed no difference between both groups (p = 0.36).
Conclusions: The present study shows that in patients with cardiac reoperation, TAVI comes with similar
outcomes when compared to surgical AVR. On the other hand, conventional redo-AVR is still a valuable
and safe treatment option.
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Surgical aortic valve replacement (AVR) is a highly standard-
ized, well-established procedure and is currently the therapeutic
gold standard for symptomatic aortic stenosis [1]. Recently, the
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0914-5087/ 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsof conventional surgical AVR [2]. Within this registry, 30-day
mortality for primary isolated AVR in Germany has been reported
as a percentage of 2.4% [3]. As patients are getting older and live
longer, due to their primary heart operation, reoperative cardiac
surgery is an increasing and integrative part of the cardio-surgical
daily practice. Although increased experience and technical
evolution lead to considerably improved outcomes, prior cardiac
surgery still represents a signiﬁcant risk factor inﬂuencing
morbidity and mortality. Especially in high-risk patients, cardiac
reoperation might be challenging.
The purpose of the present study was therefore to compare the
outcomes of high-risk patients presenting with symptomatic
degenerative aortic stenosis with prior cardiac surgery undergoing reserved.
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treated with conventional surgical AVR.
Materials and methods
Study design
The present study was a non-randomized, single-center study
including 378 patients who underwent either transcatheter aortic
valve implantation (n = 142) or surgical AVR (n = 236) at the West-
German Heart and Vascular Center Essen between 2007 and
2014. Propensity score matching (m:n) resulted in a total of
62 patients (group 1) with previous cardiac surgery who were
treated by TAVI either by the transfemoral (n = 68) or transapical
access (n = 74), and 51 patients underwent a surgical redo-AVR
(group 2). The present study obtained IRB approval according to
the Declaration of Helsinki. An individual patient consent was
waived. TAVI was only considered in high-risk patients with a
logistic EuroSCORE-I greater than 20%, or if patients were deemed
to be at high risk due to the presence of other coexisting illnesses
not reﬂected by the EuroSCORE. Moreover, the indication for TAVI
in the individual patient was discussed for each patient in an
interdisciplinary consensus conference (‘‘heart-team’’) of cardiol-
ogists and cardiac surgeons (D.W., P.K., F.A., and M.T.), and the
patient’s or physician’s preference alone was not considered
adequate for decision-making. Both, the transfemoral and transa-
pical route were considered as potential access sites for TAVI,
depending on suitability.
Inclusion and exclusion criteria
Surgical AVR
Patients with prior cardiac surgery and severe symptomatic
aortic stenosis (aortic valve area <1.0 cm2) were considered for
surgical AVR, if only the calciﬁed aortic valve had to be treated,
except additional myectomy, aortic root enlargement, or simple
wrapping of the ascending aorta. Patients with endocarditis were
excluded.
Study endpoints and deﬁnitions
The primary study endpoint was in-hospital mortality, deﬁned
as all causes of death within 30 days, including all patients. A
follow-up was also performed. Patient and operative demo-
graphics were recorded in a prospective institutional database
and retrospectively evaluated. Echocardiographic data were stored
in an institutional parallel workﬂow platform (Horizon Cardiolo-
gyTM, Medcon/McKESSON, San Francisco, CA, USA). Chronic
obstructive pulmonary disease (COPD) was deﬁned as per the
EuroSCORE deﬁnition. Survival was obtained by active follow-up.
All outcomes were reported according to the standardized VARC-2
criteria (Valve Academic Research Consortium).
TAVI procedure
Transapical
All transapical TAVIs were performed under general anesthesia
in a dedicated hybrid operation room offering full functionality for
cardiac catheterization, anaesthesiology, and cardiac surgery and a
cardiopulmonary bypass circuit and clinical perfusion team were
kept on stand-by. Competences of the interdisciplinary heart-
team, consisting of cardiac surgeons, cardiologists, anesthesiolo-
gists, and perfusionists, complemented in optimal support during
the TAVI procedure. The transapical access was performed as
previously described by our group [4]. Either the pericardium was
opened and adhesiolysis was performed or the pericardium wasunaltered, and the correct apical position was then detected by
transesophageal echocardiography. For the transapical access, only
the balloon-expandable Edwards Sapien or Sapien XT valve was
used (Edwards Lifesciences, Irvine, CA, USA).
Transfemoral
All transfemoral transcatheter aortic valve implantations were
performed within the same setting as described above, but under
conscious sedation as previously described by our group [5]. For
transfemoral implantation, both, the Edwards and the self-
expandable Medtronic CoreValve (Medtronic, Minneapolis, MN,
USA) systems were used. All TAVI patients received a lifetime
standard therapy of 100 mg acetylsalicylic acid and 75 mg
clopidogrel for 6 months.
Surgical AVR
All patients underwent computed tomography to evaluate the
distance between heart and sternum. In case of cardiosternal
contact, a femoro-femoral extracorporeal bypass was performed.
All operations were carried out through a standard median
repeated sternotomy followed by adhesiotomy and identiﬁcation
of the cardiac structures. All bypass grafts were identiﬁed. In case
of no cardiosternal contact, cardiopulmonary bypass was per-
formed (CPB) with ascending aorta cannulation. The cardiopulmo-
nary bypass was established with a single atrial cannula. Moderate
hypothermia (28–32 8C) was obtained. Myocardial protection was
achieved by antegrade and optional retrograde crystalloid
cardioplegic arrest (Custodiol1, Dr. Ko¨hler Chemie, Bensheim,
Germany) and additional topic cooling. According to our institu-
tional protocol, a patent left internal in mammary bypass graft
would also be dissected and clamped during aortic cross-clamping.
A hockeystick aortotomy with subsequent removal of the native
aortic valve and debridement of the native annulus and aortic root
was performed. After sizing the annulus with a respective
industry-labeled sizer, the prosthesis was carefully chosen. When
an effective oriﬁce area index (EOAI) >0.85 cm2/m2 would not be
achieved because of small annulus, a Manougian procedure was
performed to avoid prosthesis-patients mismatch. Patients re-
ceived either a mechanical or a biological prosthesis depending on
the patients’ preference.
Risk calculation
The EuroSCORE-I and -II calculator available online (http://
www.euroscore.org) was used for both additive (AES) and logistic
EuroSCORE (LES) and EuroSCORE-II calculations. The Society of
Thoracic Surgeons (STS)-Score was performed by the online
available STS-Score calculator (http://riskcalc.sts.org/de.aspx).
The age, creatinine, and ejection fraction (ACEF) score were
calculated as published by Ranucci and coworkers (age divided by
ejection fraction, with 1 point added if the preoperative creatinine
is 2.0 mg/dL) [6].
Statistics
Descriptive statistics are summarized for categorical variables
as frequencies and proportions (%). Continuous variables were
reported as mean  standard deviation. New York Heart Association
(NYHA) class is presented as a median. A stratiﬁed analysis based on
the propensity score (using 5 strata) was performed based on
12 patients’ major risk factors. The following factors were used for the
propensity score calculation: age, gender, left ventricular ejection
fraction, renal disease, peripheral vascular disease, EuroSCORE-I,
EuroSCORE-II, STS-Score, COPD, pulmonary hypertension, diabetes
mellitus, and NYHA-functional class. Groups were compared using
Table 1
Patient baseline characteristics.
Variable Group 1
(n = 62)
Group 2
(n = 51)
p-Value
Demographics
Age, years 78.7  5.9 71.1  10.8 <0.001
Gender, female 19 (30.6) 13 (25.5) 0.67
BMI, kg/m2 27.1  4.1 26.6  3.7 0.53
Risk factors and comorbidities
NYHA class (range) 3 (2–4) 3 (2–4) –
Peripheral vascular disease 32 (52.4) 15 (29.4) 0.02
Systemic hypertension 57 (91.9) 45 (88.2) 0.54
COPD 16 (25.8) 17 (33.3) 0.42
Renal disease
(serum creatinine
>200 mmol/L)
12 (23.5) 13 (21.0) 0.82
Diabetes mellitus 24 (38.7) 22 (43.1) 0.71
Cardiac history
LV-EF, % 48.1  13.0 49.9  12.3 0.44
LV-EF, <35% 14 (22.6) 6 (11.8) 0.15
Pulmonary hypertension 14 (22.6) 7 (13.7) 0.33
Atrial ﬁbrillation 14 (22.6) 13 (25.5) 0.82
Previous cardiac surgery 62 (100.0) 51 (100.0) 1.00
Isolated CABG surgery 54 (87.1) 33 (64.7) <0.01
CABG + mitral valve surgery 1 (1.6) 1 (1.9) 1.00
Isolated mitral valve surgery 1 (1.6) 5 (9.8) 0.09
Isolated aortic valve surgery 2 (3.2) 10 (19.6) <0.01
Aortic valve + CABG 4 (6.5) 2 (3.9) 0.69
Patent IMA-graft 58 (93.5) 51 (100.0) 0.13
Risk scores
STS-Score, % 12.1  10.0 7.1  5.2 <0.01
Logistic EuroSCORE-I, % 36.4  17.4 22.2  17.5 <0.01
Additive EuroSCORE-I, % 12.9  2.9 10.1  2.9 <0.01
EuroSCORE-II, % 13.0  9.2 9.2  7.2 <0.01
ACEF-Score, % 1.9  0.8 1.6  0.6 <0.01
Data are presented as mean  SD or number (%), NYHA class presented as median;
BMI, body mass index; NYHA, New York Heart Association; COPD, chronic
obstructive pulmonary disease; LV, left ventricle; EF, ejection fraction; STS, Society
of Thoracic Surgeons; EuroSCORE, European System for Cardiac Operative Risk
Evaluation.
Table 2
VARC-2 criteria.
Variable Group 1 (n = 62) Group 2 (n = 51)
Mortality
30-Day all cause 9 (14.5) 3 (5.8)
30-Day cardiovascular 1 (1.6) (1.6)
12-Month all cause 14 (22.6) 7 (13.7)
Stroke 30-day 0 (0) 1 (2.0)
Major bleeding 5 (8.0) 2 (3.9)
Life-threatening bleeding 2 (3.2) 1 (2.0)
Pacemaker implantation 11 (17.7) 1 (2.0)
Dialysis 7 (11.3) 3 (5.9)
Data are presented as number (%); VARC, Valve Academic Research Consortium.
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logistic regression analyses were performed to identify preoperative
independent risk factors for in-hospital mortality. For the analysis of
mortality, those variables identiﬁed by the univariate analysis with a
p-value <0.1 were added to the multivariable model, including group
membership (belonging to one of both groups). Survival curves were
generated with the Kaplan–Meier method followed by a log-rank test.
In addition, uni- and multivariate Cox’s proportional hazards models
were applied to analyze the survival times and their relationship to the
other variables. The proportional hazards assumption was further-
more veriﬁed with log–log survival plots. For those risk factors, which
have been identiﬁed to signiﬁcantly affect 30-day mortality, receiver
operating curves (ROCs) were calculated. Sensitivity and speciﬁcity of
expected vs. observed mortality were summarized by ROCs and the
area under the resulting curve (AUC). A decreasing value of this
statistic from 1.0 toward 0.5 indicates decreasing distinctiveness or
discrimination between patients living and dead. Results were given as
AUC accompanied by 95% conﬁdence intervals.
A p-value less than 0.05 was considered to indicate statistical
signiﬁcance. All statistical analyses were performed using SAS1,
version 9.2 (SAS Inc., Cary, NC, USA).
Statement of responsibility
The authors had full access to the data and take full
responsibility for its integrity. All authors have read and agreed
to the manuscript as written.
Results
Preoperative characteristics of both groups are summarized in
Table 1. Both groups were similar for all listed characteristics, except
for age, peripheral vascular disease, and the calculated risk scores.
Patients in group 1 were signiﬁcantly older (78.1  5.9 years vs.
71.1  10.8 years, p < 0.01), and showed more peripheral vascular
disease than patients in group 2 (52.4% vs. 29.4%, p = 0.02). Further-
more, preoperative risk assessment showed higher estimated risk
scores for group 1 (logistic EuroSCORE-I 36.4  17.4% vs. 22.2  17.5%,
p < 0.01, additive EuroSCORE-I 12.9  2.9% vs. 10.1  2.9%, p < 0.01,
EuroSCORE-II 13.0  9.2% vs. 9.2  7.2%, p < 0.01, ACEF-Score
1.9  0.8% vs. 1.6  0.6%, p < 0.01, and STS-Score 12.1  10.0% vs.
7.1  5.2%, p < 0.01). Patients in group 1 had signiﬁcantly more isolated
coronary artery bypass graft (CABG) surgery as previous cardiac
surgery, whereas patients in group 2 had signiﬁcantly more isolated
aortic valve surgery (p < 0.01). A detailed summary of all underlying
types of previous cardiac surgery is presented in Table 1.
Postoperative outcomes
There was no difference in 30-day mortality between the two
groups. 30-Day mortality was 14.5% (9/62) in group 1 compared to
5.8% (3/51) in group 2 (p = 0.23). Outcomes according to VARC-2
are given in Table 2.
Survival
Freedom from all-cause death in group 1 was 77.4% at 1 year,
72.5% at 2 years, 59.5% at 3 years, 54.3% at 4 years, and 30.1% at
5 years. In group 2, freedom from all-cause death was 86.3% at
1 year, 80.0% at 2 years, 73.8% at 3 years, 71.5% at 4 years, and 68.9%
at 5 years. Kaplan–Meier survival curves are given in Fig. 1.
Regression analysis
In order to evaluate independent predictors for 30-day
mortality, a logistic regression model was constructed, based on12 major risk factors. Several univariate indicators were found to
predict for 30-day mortality. In the univariate model, the following
variables were found to be strongly associated with 30-day
mortality: logistic EuroSCORE-I, EuroSCORE-II, and STS-Score
(Table 3). The multivariable regression model showed that only
the logistic EuroSCORE-I [odds ratio (OR) 1.054; 95% conﬁdence
interval (CI), 1.007–1.104; p = 0.02] was signiﬁcantly associated
with 30-day mortality. Most notably, group membership was not
associated with 30-day mortality (p = 0.21) (Table 3). In a next step,
a Cox’s proportional hazards regression model of survival was
constructed. The univariate model found the following variables to
be strongly associated with survival: ejection fraction, logistic
EuroSCORE-I, EuroSCORE-II, STS-Score, and NYHA-functional class
(Table 4). The multivariable model showed that the logistic
Fig. 1. Kaplan–Meier survival curves; gray line: group 1; black line: group 2. TAVI,
transcatheter aortic valve implantation; AVR, aortic valve replacement.
Table 3
Univariate and multivariate regression analysis of variables associated with 30-day mo
Variable Univariate analysis 
OR CI 
Group membership 0.332 0.086–1.279 
Gender 1.314 0.337–5.133 
Age 1.079 0.978–1.190 
Ejection fraction 0.960 0.978–1.005 
Renal insufﬁciency 1.871 0.521–6.728 
Peripheral artery disease 2.462 0.750–8.074 
Logistic EuroSCORE-I 1.062 1.028–1.097 
EuroSCORE-II 1.088 1.024–1.157 
STS-Score 1.064 1.016–1.115 
COPD 1.585 0.477–5.261 
Pulmonary hypertension 2.144 0.591–7.776 
Diabetes mellitus 1.795 0.561–5.740 
NYHA 0.948 0.109–8.255 
OR, odds ratio; CI, conﬁdence interval.
Table 4
Univariate and multivariate Cox’s proportional hazards regression model of survival ti
Variable Univariate analysis 
HR CI 
Group membership 0.621 0.322–1.201 
Gender 0.984 0.517–1.873 
Age 1.032 0.996–1.068 
Ejection fraction 0.975 0.953–0.998 
Renal insufﬁciency 1.248 0.632–2.465 
Peripheral artery disease 1.639 0.897–2.995 
Logistic EuroSCORE-I 1.036 1.020–1.052 
EuroSCORE-II 1.044 1.016–1.072 
STS-Score 1.034 1.010–1.059 
COPD 1.094 0.583–2.053 
Pulmonary hypertension 1.140 0.548–2.369 
Diabetes mellitus 1.795 0.646–2.072 
NYHA 4.566 1.625–12.831 
HR, hazard ratio; CI, conﬁdence interval.
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p = 0.01], the STS-Score (HR 1.039; 95% CI 1.003–1.077; p = 0.03),
and NYHA-functional class (HR 6.531; 95% CI 2.109–20.220;
p = 0.001) were signiﬁcantly associated with survival (Table 4).
Importantly, after ﬁnal adjustment of the Cox’s proportional hazards
regression model for the propensity score, group membership
remained not signiﬁcant (HR, 0.651; 95% CI, 0.257–1.651, p = 0.36).
ROC analysis
As the logistic EuroSCORE-I was identiﬁed to signiﬁcantly
inﬂuence 30-day mortality, a ROC analysis was performed for the
logistic EuroSCORE-I. The AUC was 80.1 for the logistic EuroSCORE-I
(CI 66.3–93.9) for all patients (n = 113) and 87.9 for group 2 (CI
70.7–100.0), whereas group 1 showed an AUC of 73.6 (CI 53.5–93.6).
The ROC analysis of the EuroSCORE-I for all patients is shown in
Fig. 2.
Discussion
The present study compared high-risk patients with previous
cardiac surgery and new symptomatic aortic stenosis undergoing
either TAVI or a surgical reoperation strategy. This study provides a
number of interesting ﬁndings:
1. Although TAVI patients were older and showed higher risk
scores, we observed no statistically signiﬁcant difference
concerning 30-day mortality.rtality.
Multivariate analysis
p-Value OR CI p-Value
0.109 0.314 0.052–1.889 0.21
0.694 – – –
0.128 – – –
0.078 0.992 0.934–1.053 0.786
0.337 – – –
0.1372 – – –
<0.001 1.054 1.007–1.104 0.02
<0.001 0.975 0.889–1.069 0.588
<0.001 1.062 0.995–1.132 0.068
0.452 – – –
0.246 – – –
0.324 – – –
0.961 – – –
mes.
Multivariate analysis
p-Value HR CI p-Value
0.157 1.164 0.510–2.659 0.718
0.961 – – –
0.079 1.019 0.981–1.059 0.321
0.031 0.996 0.968–1.024 0.767
0.523 – – –
0.108 – – –
<0.001 1.031 1.006–1.057 0.01
<0.001 0.979 0.933–1.027 0.389
0.01 1.039 1.003–1.077 0.03
0.779 – – –
0.726 – – –
0.624 – – –
0.004 6.531 2.109–20.220 0.001
Fig. 2. ROC curves for the logistic EuroSCORE-I for all patients (n = 113) in regard to
30-day mortality.
D. Wendt et al. / Journal of Cardiology 66 (2015) 292–2972962. Multivariate regression analysis showed the logistic Euro-
SCORE-I to signiﬁcantly affect 30-day mortality in patients
with previous cardiac surgery.
3. The logistic EuroSCORE-I showed a good performance in our
overall cohort of redo patients with an AUC of 80.1.
4. Surgical AVR showed excellent long-term results in patients
with previous cardiac surgery.
Surgical AVR still represents the therapeutic golden standard in
the treatment of aortic stenosis with excellent long-term out-
comes, which have been proven by the recently published GARY
data [2,3]. Within this registry, 30-day mortality for isolated
surgical AVR has been reported to be as low as 2.4%, and 6.7% at
1 year, respectively, and one should bear in mind, that a total of
9.4% of these patients had undergone previous cardiac surgery
[2]. In conventional surgical AVR, it is well-known that previous
cardiac surgery represents an independent risk factor, which is
associated with increased morbidity and mortality compared with
ﬁrst-time surgery. One surgical series reported a 11-fold increase
for 30-day mortality in patients with previous CABG undergoing
redo-AVR [7]. In a previous evaluation, we published an OR of 3.3
(95% CI 1.1–10.2) for repeat cardiac surgery in our institution
[8]. Cardiac re-exploration in cases of patent internal mammary
artery (IMA) might increase surgical risk. In the present study, all
IMA-grafts in the surgically treated group and 93.5% in the TAVI-
treated group were patent. In our institution, the operative
standard is to dissect and free the patent IMA-graft in order to
clamp it during cardiac arrest, thereby preventing both regional
myocardial warming and cardioplegia-‘‘washout’’ during clamp-
ing. If the IMA-graft could not be clearly identiﬁed, a sterile
ultrasound probe was used (Medistim, Oslo, Norway).
As a minimally invasive alternative, TAVI has evolved to
become the new standard of care for inoperable patients with
severe, symptomatic aortic valve stenosis [9] and to be a viable
treatment option for high-risk, but operable patients [10], as
recently demonstrated in the Placement of Aortic Transcatheter
Valves (PARTNER) trial, and also in patients with previous renal
transplantation [11]. In contrast to large aortic valve registries,cohort A of the randomized PARTNER trial presented a somewhat
huge number of patients with previous cardiac surgery (42.6% of
the TAVI group and 44.2% in the surgical AVR group). Greason et al.
recently published a PARTNER trial subgroup analysis including
only patients (n = 288) with prior CABG operation, who were
treated either by TAVI (51%) or surgical AVR (49%). There was no
difference in 30-day mortality (16.7% vs. 16.3%, p = 0.95), but a
trend toward greater 2-year all-cause mortality in the TAVI-treated
patients (36% vs. 25%; p = 0.052). Interestingly, they described no
association of paravalvular regurgitation in the TAVI group (9%)
with the 2-year outcome (p = 0.011) [12].
Despite these publications, there are limited data evaluating the
impact of previous cardiac surgery on long-term outcomes. For
exactly that reason, it appears reasonable to evaluate the outcomes
of patients with previous cardiac surgery undergoing either
surgical AVR or percutaneous TAVI.
In a recent publication, Wilbring et al. evaluated transapical
TAVI vs. surgical AVR in high-risk patients with previous cardiac
surgery by propensity score analysis. A total of 53 patients per
group were matched, and in regard to 30-day mortality, they
observed no difference between both groups (5.7% in the surgical
control group and 9.4% in the TAVI group) [13], similar to our
results (5.8% in surgical redo-AVR vs. 14.5% in the TAVI group). It
must be emphasized, however, that our institutional TAVI program
started in 2005 with the transfemoral, and in 2007 with the
transapical approach. Therefore, within the present study some
patients were matched, who reﬂect our early experience with
TAVI, which might explain the relatively high 30-day mortality in
group 1.
Although we performed a profound m:n matching of both
groups, the results showed a statistical signiﬁcance of preoperative
risk scores and age between both groups. On the other side,
however, we could show by detailed multivariate analysis, that
group membership had no inﬂuence on 30-day mortality, despite
such different preoperative risk scores.
Of note, in the absence of data evaluating the long-term
outcomes of TAVI patients, the present study provides compre-
hensive follow-up data up to 5 years after TAVI/surgical AVR in
patients with repeated cardiac surgery as we have been one of the
pioneering centers in Germany starting with TAVI. In the surgical
group, we observed excellent outcomes, despite the independent
risk of previous cardiac surgery with 1-year survival rates of 86.3%
and 68.9% at 5 years. This is in line with previous published data,
showing survival rates of 93.4% at 1 year and 75.8% at 5 years in
isolated surgical AVR [1]. For comparison, the 1-year survival rates
of the PARTNER cohort A for surgical AVR were 73.2% [10]. On the
other hand, TAVI-treated patients of cohort A within the PARTNER
trial showed a 1-year survival rate of 75.8%, which could be
reﬂected by our results with 1-year survival rates of 77.4%.
However, evaluating our long-term results, we observed a
statistically signiﬁcant difference between both groups with better
survival in the conventional AVR group (p < 0.001), which can be
attributed to the fact that in our series, TAVI patients were
signiﬁcantly older.
Furthermore, as we identiﬁed the logistic EuroSCORE-I to
signiﬁcantly impact 30-day mortality in patients with previous
cardiac surgery undergoing either TAVI or surgical AVR, we
performed a ROC analysis evaluating the logistic EuroSCORE-I. Our
group has previously shown that in conventional surgical AVR the
STS-Score appears to be more appropriate for risk prediction,
which could be proven in a future study evaluating also TAVI
patients [14]. In the present study, however, as all patients were
redo patients, the logistic EuroSCORE-I showed a good perfor-
mance with an AUC of 80.1 (CI 66.3–93.9). Moreover, in the
subgroup of patients treated by surgical AVR, the AUC was even
better with 87.9 (CI 70.7–100.0). It is well known that the logistic
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Improvements in cardio-surgical techniques since then may mean
that EuroSCORE-I is currently inappropriately calibrated. It is also
important to note that some risk scoring systems include mainly
data of CABG patients, rather than those undergoing AVR. In the
present study, we observed a good c-statistics for the logistic
EuroSCORE-I in redo patients. This might be related to the fact that
in redo cases, of course, the operative risk is higher, and therefore
the logistic EuroSCORE-I might predict better.
In cardiac surgery, high-risk patients presenting with symp-
tomatic aortic stenosis and with previous cardiac surgery
represent a challenging patient cohort. In particular, patients with
previous CABG surgery are at risk for graft injury during re-
exploration. On the one hand, despite the potential risk of
reoperation, the surgical approach comes with excellent long-
term outcomes as supported by the results of the present
evaluation. On the other hand, however, TAVI represents a
minimally invasive alternative without the need for complete
re-exploration and extracorporeal circulation or even myocardial
arrest. Therefore, TAVI might be particularly helpful in elderly
high-risk redo patients. To this extent, it remains to discuss a
broadened indication of TAVI in the future in the reoperative
situation.
Limitations
The present study was performed at a single tertiary care
medical center starting with TAVI in 2005, and the matching
resulted in a relatively small sample size. Therefore, the generali-
zation of our ﬁndings may not extend to all centers worldwide. In
addition, as patients of our early experience have also been
included, results might be mixed due to the learning curve of the
new technique of TAVI and of note, recent results of TAVI are nearly
comparable to conventional AVR. In addition, our model of
propensity matching might have missed some relevant factors.
Conclusion
In conclusion, our study showed no difference in regard to
30-day mortality in patients with previous cardiac surgery
undergoing either TAVI or surgical AVR. However, it should be
kept in mind, that despite best matching, the TAVI group was still
signiﬁcantly older and had higher risk scores. Against this
background, one must consider these differences between both
groups with a nearly doubled logistic EuroSCORE-I in the
percutaneous-treated group. In our study, we showed that
multivariate regression analysis revealed the logistic Euro-
SCORE-I to signiﬁcantly affect 30-day mortality, and a high AUC
was observed for the logistic EuroSCORE-I especially in conven-
tional reoperative AVR patients. Moreover, and most interestingly,
one treatment strategy (TAVI) evolved simultaneously while the
other has been used for decades as the standard of care. As a result,
as short-term mortality shows no difference, TAVI might be
particularly helpful in elderly high-risk redo patients, although we
showed a signiﬁcant difference in ‘‘mid-term’’ results up to 5 years.
However, surgical redo-AVR is still a good option, except in very
high-risk patients. To this extent, it remains to discuss a broadened
indication of TAVI in the future in the reoperative situation.
Therefore, further studies with larger patient numbers as well as
randomized clinical trials with longer follow-up are warranted
since we were able to present only ‘‘mid-term’’ results.Funding sources
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